Lenvamed 4mg Capsule contains Lenvatinib, a multi-kinase inhibitor used primarily in the treatment of certain types of cancer. Lenvatinib exerts its therapeutic effect by inhibiting the activity of multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. This mechanism helps to reduce tumor growth and metastasis. Lenvamed 4mg is indicated for the treatment of differentiated thyroid cancer refractory to radioactive iodine therapy, advanced renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma in patients who have received prior systemic therapy. The capsule formulation allows for oral administration, facilitating ease of use in outpatient settings. Dosage and duration of treatment should be individualized based on patient response and tolerability, with careful monitoring for adverse effects such as hypertension, proteinuria, fatigue, diarrhea, and hepatotoxicity. Regular assessment of blood pressure, liver function tests, and renal function is recommended during therapy. Lenvamed should be prescribed and administered under the supervision of an oncologist or healthcare professional experienced in cancer management. Patients are advised to report any unusual symptoms promptly to ensure timely intervention and optimize therapeutic outcomes.